<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071174</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 015</org_study_id>
    <nct_id>NCT01071174</nct_id>
  </id_info>
  <brief_title>A Safety Study of Dapivirine Vaginal Ring in Africa</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety of an Intravaginal Matrix Ring With Dapivirine in Healthy, HIV-Negative Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled Phase I/II study to assess the safety
      of a silicone elastomer vaginal ring containing 25mg dapivirine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as determined by the proportion of women in each arm experiencing protocol-specified events, including AEs, laboratory abnormalities, cervico-vaginal abnormalities, abnormal vaginal flora/pH during the study.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the product determined by questionnaire.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the protocol-specific product regimen as determined by self-report and clinician observation at each study visit.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo Ring</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vaginal Ring containing no drug substance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapivirine Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapivirine Vaginal Ring 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dapivirine</intervention_name>
    <description>Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)</description>
    <arm_group_label>Dapivirine Ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaginal Ring containing no drug substance</description>
    <arm_group_label>Placebo Ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18 and 40 years of age inclusive who can provide informed consent

          -  Available for all visits and consent to follow all procedures scheduled for the study

          -  Healthy and self-reported sexually active

          -  HIV-negative

          -  On a stable form of contraception and willing to continue OR have undergone surgical
             sterilization at least 3 months prior to enrollment

          -  In the absence of the use of exogenous hormone(s), have a self-reported regular
             menstrual cycle defined as having a minimum of 21 days and a maximum of 35 days
             between menses

          -  Upon pelvic/speculum examination and colposcopy at the time of enrolment, the cervix
             and vagina appear normal as determined by the investigator

          -  Asymptomatic for genital infections at the time of enrolment

          -  Willing to refrain from use of vaginal products or objects within 14 days from
             enrollment and for the duration of the study

          -  Willing to answer to acceptability, adherence and behavioural assessments throughout
             the study

          -  Willing to refrain from participation in any other research study for the duration of
             their participation

          -  Willing to provide adequate locator information for study retention purposes and be
             reachable per local standard procedures

        Exclusion Criteria:

          -  Currently pregnant or last pregnancy within 3 months prior to enrolment

          -  Currently breast-feeding

          -  Participated in any other research study within 60 days prior to screening

          -  Previously participated in any HIV vaccine study

          -  Untreated urogenital infections within 2 weeks prior to enrolment

          -  Presence of any abnormal physical finding on the vulva, vaginal walls or cervix during
             pelvic/speculum examination and/or colposcopy

          -  History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,
             or urethral obstruction, incontinence or urge incontinence

          -  Pap smear result at screening that requires cryotherapy, biopsy, treatment or further
             evaluation

          -  Any Grade 2, 3 or 4 baseline (screening) haematology, chemistry or urinalysis
             laboratory abnormality according to the DAIDS Table for Grading Adverse Events

          -  Any abnormal bleeding per vagina, bleeding per vagina during or following vaginal
             intercourse, or gynaecologic surgery within 90 days prior to enrolment

          -  Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of
             sensitivity/allergy to latex or silicone elastomer

          -  Any serious acute, chronic or progressive disease

          -  Any condition(s) that, in the opinion of the investigator, might interfere with
             adherence to study requirements or evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Annalene Nel</last_name>
    <role>Study Director</role>
    <affiliation>IPM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya Medical Research Institute (KEMRI)</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Project</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Health and HIV Research Unit (RHRU)</name>
      <address>
        <city>Edendale</city>
        <state>Kwazulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo</name>
      <address>
        <city>Ladysmith</city>
        <state>Kwazulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prevention for HIV and AIDS Project (PHIVA)</name>
      <address>
        <city>Pinetown</city>
        <state>Kwazulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madibeng Centre for Research</name>
      <address>
        <city>Brits</city>
        <state>North West</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation Masiphumelele</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation Nyanga</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre Mbekweni</name>
      <address>
        <city>Paarl</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical Centre (KCMC)</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>Rwanda</country>
    <country>Zambia</country>
  </removed_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Annalene Nel, MBChB, PhD</name_title>
    <organization>International Partnership for Microbicides</organization>
  </responsible_party>
  <keyword>HIV infections</keyword>
  <keyword>Anti-HIV agents</keyword>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

